GSK (GSK)

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Company profile

Ticker

GSK

Exchange

NYSE

Website

www.gsk.com/

CEO

Emma Walmsley

Incorporated

United Kingdom

Location

United Kingdom

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

Former names

GLAXOSMITHKLINE PLC

SEC CIK

0001131399

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

GSK stock data

1M 1Y 5Y

News

From Benzinga Pro

GlaxoSmithKline: Dividend Insights

16 May 22

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

12 May 22

GSK's Panadol and Sensodyne-maker Haleon in Talks to Hire Banks

3 May 22

-Sky News https://news.sky.com/story/gsks-45bn-panadol-and-sensodyne-maker-haleon-in-talks-to-hire-banks-12604875

GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine

27 Apr 22

GlaxoSmithKline Earlier Reported Q1 EPS $0.88 Beats $0.76 Estimate, Sales $13.13B Beat $11.70B Estimate

27 Apr 22

Press releases

From Benzinga Pro

SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

5 May 22

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Sierra Oncology, Inc (NASDAQGM:SRRA) to GlaxoSmithKline plc

Voltaren Teams Up with Actress Jennie Garth to Support Caregivers Nationwide

4 May 22

In partnership with the actress and caregiver, the brand kicks off CareWalks, a pledge to caregivers across the country that offers resources and encourages movement through a new video series, a charitable donation and

SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

2 May 22

Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NASDAQGM:SRRA) to GlaxoSmithKline plc (NYSE:GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only

MOBI Makes Their Post-Pandemic NYC Debut

2 May 22

SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA

25 Apr 22

Calendar

8 Mar 22

20 May 22

Financial summary

Financial statements Chart GSK financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from GSK earnings reports.

Recent insider trades

GSK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Jul 21	GSK	Common Stock	Buy	Acquire P	Yes	No	18	275,000	4.95M	1,007,583
2 Jul 21	GSK	Common Stock	Conversion	Acquire C	Yes	No	0	635,646	0	732,583
2 Jul 21	GSK	Common Stock	Conversion	Acquire C	Yes	No	0	27,345	0	96,937
2 Jul 21	GSK	Common Stock	Conversion	Acquire C	Yes	No	0	8,380	0	69,592
2 Jul 21	GSK	Common Stock	Conversion	Acquire C	Yes	No	0	14,917	0	61,212
2 Jul 21	GSK	Common Stock	Conversion	Acquire C	Yes	No	0	12,979	0	46,295
2 Jul 21	GSK	Common Stock	Conversion	Acquire C	Yes	No	0	1,505	0	33,316
2 Jul 21	GSK	Series G Preferred Stock Common Stock	Conversion	Dispose C	Yes	No	0	10,055,408	0	0
2 Jul 21	GSK	Series F-2 Preferred Stock Common Stock	Conversion	Dispose C	Yes	No	0	1,081,434	0	0
2 Jul 21	GSK	Series E-2 Preferred Stock Common Stock	Conversion	Dispose C	Yes	No	0	331,399	0	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

GSK institutional ownership history Ownership history

13.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	884	890	-0.7%
Opened positions	104	187	-44.4%
Closed positions	110	67	+64.2%
Increased positions	331	307	+7.8%
Reduced positions	258	238	+8.4%

13F shares	Current	Prev Q	Change
Total value	14.37B	14.41B	-0.3%
Total shares	330.32M	326.9M	+1.0%
Total puts	3.95M	2.62M	+51.0%
Total calls	4.88M	10.78M	-54.7%
Total put/call ratio	0.8	0.2	+233.7%

Largest owners	Shares	Value	Change
Dodge & Cox	85.75M	$3.74B	-3.1%
Capital International Investors	19.1M	$832.01M	-0.1%
Fisher Asset Management	18.97M	$826.21M	+4.1%
FMR	16.92M	$736.84M	-4.7%
TROW T. Rowe Price	15.19M	$661.56M	+0.4%
Renaissance Technologies	10.01M	$436.12M	-2.1%
Arrowstreet Capital, Limited Partnership	9.62M	$419.11M	+32.5%
Black Creek Investment Management	9.21M	$401.13M	-11.2%
JTC Employer Solutions Trusteee	9.02M	$392.74M	+50.4%
STT State Street	8.99M	$397.4M	-0.1%

Largest transactions	Shares	Bought/sold	Change
JTC Employer Solutions Trusteee	9.02M	+3.02M	+50.4%
Dodge & Cox	85.75M	-2.77M	-3.1%
NMR Nomura	1.94M	-2.45M	-55.8%
Arrowstreet Capital, Limited Partnership	9.62M	+2.36M	+32.5%
GS Goldman Sachs	7.11M	+2.32M	+48.3%
Marshall Wace	2.23M	+2.23M	NEW
Two Sigma Investments	7.16K	-1.92M	-99.6%
Acadian Asset Management	3.4M	+1.61M	+90.1%
Camber Capital Management	1M	-1.5M	-60.0%
Healthcare Of Ontario Pension Plan Trust Fund	0	-1.3M	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Cytrx • Heron Therapeutics • Geovax Labs • Mosaic ImmunoEngineering • Immunogen • Delcath Systems • ARIAD Pharmaceuticals • Adamis Pharmaceuticals • Titan Pharmaceuticals, Inc. • FibroGen

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accessible, adjuvant, Africa, ambition, andXevudy, Anne, antibody, antisense, August, Beal, bepirovirsen, bictegravir, Biktarvy, box, cabotegravir, cabozantinib, Canadian, cancer, categorisation, cephalosporin, CH, characterised, circa, circulation, clarity, cohort, CombinedTivicay, component, COVID, depemokimab, Device, Diagnostic, Dietz, difficult, digitalisation, disappointing, disciplined, distancing, distrust, dosing, drag, drove, Endorsement, engineering, exceeding, exemplar, FluLaval, freight, fuelling, fulfilment, geopolitical, Gilead, GLT, guided, Haleon, halving, HBV, headroom, hemisphere, hesitancy, highlighted, ID, immunology, inBlenrep, includingNucala, includingSeretide, inDovato, Ineffective, inflationary, inFluarix, infringement, Ingredient, inhaled, injectable, internationally, invalidating, invasion, labour, lethality, licence, lowerShingrix, maximising, meaningfully, misinformation, monetise, monoclonal, mRNA, ofArnuity, ofXevudy, oligonucleotide, omnichannel, onset, ovarian, payout, percent, perception, pharma, PIPL, pivotal, plastic, predict, preparatory, preserve, primarilyShingrix, quantify, rare, raw, rebound, rebounded, regimensJuluca, Rejection, reliant, render, retaliatory, risky, RSV, run, Russia, Ryan, slightly, Smoker, southern, sovereignty, Spain, stable, staffing, suppressed, susceptible, synthetic, temporary, theTivicay, tolerance, toXyzal, track, treatmentsand, tubing, Ukraine, underperform, unprecedented, unrepeated, unsolicited, Vitro, whereTrelegy, White, wholly, withBenlysta, Xevudy

Removed: acceptable, accomplish, Advair, Brexit, build, candidate, capable, Cervarix, CET, collected, contaminated, content, core, cyclical, declined, deed, demerge, desired, detrimental, disaster, discounting, discourse, dramatic, emergency, evolve, execute, exit, experienced, favorable, flat, footprint, franchise, functional, impede, impeded, influenza, initiate, innate, interpreted, Judy, lawfully, leverage, Lewent, license, lose, manufacturer, marketplace, mitigation, notable, organisation, packaging, play, preferred, prevented, produce, progression, proprietary, reaching, realized, recapitalization, reimbursed, remediate, retrieval, Rotarix, selected, sharing, storage, suspension, Synflorix, Tabular, terrorism, traded, unreasonable, unrest, weaker

From filing 20-F 2021 FY

Financial reports

View all

20-F

2021 FY

Annual report (foreign)

8 Mar 22

20-F

2020 FY

Annual report (foreign)

12 Mar 21

20-F